Helper-dependent adenoviral vectors for liver-directed gene therapy.
about
Adenovirus vectors for gene therapy, vaccination and cancer gene therapyGene Therapy for Metabolic DiseasesPhysiologic and metabolic safety of butyrylcholinesterase gene therapy in miceGene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.The future potential for cocaine vaccines.Proteoglycan 4 expression protects against the development of osteoarthritisSR-A and SREC-I binding peptides increase HDAd-mediated liver transduction.Reduction of ethanol consumption in alcohol-preferring rats by dual expression gene transferNitric-oxide supplementation for treatment of long-term complications in argininosuccinic aciduria.Balloon catheter delivery of helper-dependent adenoviral vector results in sustained, therapeutic hFIX expression in rhesus macaques.SR-A and SREC-I are Kupffer and endothelial cell receptors for helper-dependent adenoviral vectors.A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA.Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuseInterception of cocaine by enzyme or antibody delivered with viral gene transfer: a novel strategy for preventing relapse in recovering drug users.Innate functions of immunoglobulin M lessen liver gene transfer with helper-dependent adenovirus.Adenovirus: the first effective in vivo gene delivery vectorHelper-Dependent Adenoviral Vectors.Cocaine hydrolase gene therapy for cocaine abuseThe evolution of adenoviral vectors through genetic and chemical surface modifications.Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hyperoxaluria type 1.Recent advances in gene therapy for lysosomal storage disorders.Sustained production of a soluble IGF-I receptor by gutless adenovirus-transduced host cells protects from tumor growth in the liver.CRISPR/Cas9: at the cutting edge of hepatology.CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.Gene transfer of master autophagy regulator TFEB results in clearance of toxic protein and correction of hepatic disease in alpha-1-anti-trypsin deficiency.High-level production of replication-defective human immunodeficiency type 1 virus vector particles using helper-dependent adenovirus vectors.Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression.In Silico Modeling of Liver Metabolism in a Human Disease Reveals a Key Enzyme for Histidine and Histamine Homeostasis.Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver.Hepatic gene therapy using lentiviral vectors: has safety been established?Challenges and Prospects for Helper-Dependent Adenoviral Vector-Mediated Gene Therapy.Feasibility of Applying Helper-Dependent Adenoviral Vectors for Cancer Immunotherapy.Beyond Gene Delivery: Strategies to Engineer the Surfaces of Viral Vectors.
P2860
Q27001601-58F45B76-5BD6-4035-993C-7EA9BB28CE42Q28595868-D39B778D-828F-49FA-8C09-F888BDFC08BDQ33831381-1FD8CA9F-8405-456C-ABC0-EA32E6ACEF77Q33881920-02DCA0D5-1EB1-47AD-906C-717D1B1EEFA5Q34132804-8DB70B01-21D0-4F97-A480-0749F06FE56FQ34619757-7633ABE2-524E-42EE-AE39-EACFCBB9883EQ35224065-ED5B8629-F506-45FF-AA7A-FB9EDC437E81Q35772588-06F2660A-BEBE-4526-8B07-7164F914FCE1Q36036579-0D4A716A-D7FF-41D4-B4D2-29326967E0F4Q36298627-E1D5F9D4-CBC1-4DA3-848C-CD3EBAB212F0Q36740254-EC26EE57-CE53-4B4A-A35F-BD38586D2D9FQ36870087-4953CB5C-FCA0-4CA6-AF4F-D22CC7375F9EQ37082158-B6A9DF46-EFD3-4B3A-B3FE-43DF6954E6FAQ37082190-3EB01136-30E8-4AAA-83C0-05D314A65137Q37499424-9A8696C7-6101-4D83-A6A1-7C03C4DE40ABQ37508260-FFD7EC47-4A60-4641-8CD8-EA3951EE37ADQ37582126-8EC6574C-8B2D-4EA8-BA2F-A71736715816Q37980864-09469C66-88FB-4FD0-9FEB-D1D9E4CF5792Q38189250-EA87E007-F9B5-41F3-ACB4-35010F865754Q38302375-5A36EEEA-7D22-466C-81F4-D7A1822EB6EAQ38546492-82E6A333-FFE8-4307-9146-A6A2A99D98D5Q39183606-A2E54851-8B67-4B18-841A-56D66C89C45CQ39294371-F0789D94-B5FC-4403-A0CC-F4F4D977F580Q40580426-6F3805D9-0ECC-4552-B41E-B737E88AA3EEQ41106554-920A4CA8-468E-4A8D-927D-60D7D0570A84Q41124092-A9449B2F-7CFA-486F-AF3A-1B8BEB79BB8FQ41627013-2EE3D7CF-C975-435C-A21A-4926A7EEF47FQ42096046-556E71D8-06EF-41F8-B20B-AF8D88099CD8Q42223027-6772201E-226F-4537-98A3-5464C313A1BAQ43730527-6EB35F6D-10EA-4E11-A44A-9A0382819A52Q50977875-EB79264B-3D9E-49C5-AC36-91C97ECB52B7Q51847569-23A8B700-3205-45A5-874F-2AA5888BF838Q51857382-EDDC2D98-92A5-48D7-BE4B-253F3E5231DB
P2860
Helper-dependent adenoviral vectors for liver-directed gene therapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Helper-dependent adenoviral vectors for liver-directed gene therapy.
@ast
Helper-dependent adenoviral vectors for liver-directed gene therapy.
@en
Helper-dependent adenoviral vectors for liver-directed gene therapy.
@nl
type
label
Helper-dependent adenoviral vectors for liver-directed gene therapy.
@ast
Helper-dependent adenoviral vectors for liver-directed gene therapy.
@en
Helper-dependent adenoviral vectors for liver-directed gene therapy.
@nl
prefLabel
Helper-dependent adenoviral vectors for liver-directed gene therapy.
@ast
Helper-dependent adenoviral vectors for liver-directed gene therapy.
@en
Helper-dependent adenoviral vectors for liver-directed gene therapy.
@nl
P2860
P356
P1476
Helper-dependent adenoviral vectors for liver-directed gene therapy
@en
P2093
P2860
P356
10.1093/HMG/DDR143
P577
2011-04-05T00:00:00Z